AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic
European Pharmaceutical Review
JULY 12, 2022
By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.
Let's personalize your content